Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey

Basit Öğe Kaydı
dc.authoridDolarslan, Murside Esra/0000-0002-8669-4212
dc.authoridYüksel, ENVER/0000-0003-0302-932X
dc.authoridAdibelli, Zelal/0000-0001-7091-5204
dc.authoridAZAK, Alper/0000-0001-6228-8829
dc.authoridDheir, Hamad/0000-0002-3569-6269
dc.authoridAyar, Yavuz/0000-0003-4607-9220
dc.authoridSahutoglu, Tuncay/0000-0003-2015-4421
dc.authorwosidPembegul, Irem/HJA-2191-2022
dc.authorwosidDolarslan, Murside Esra/D-5535-2019
dc.authorwosidYüksel, ENVER/GSN-1026-2022
dc.authorwosidAdibelli, Zelal/B-1781-2019
dc.authorwosidAZAK, Alper/AGL-5503-2022
dc.authorwosidDheir, Hamad/CAH-8663-2022
dc.authorwosidAyar, Yavuz/AGF-0767-2022
dc.contributor.authorOzturk, Savas
dc.contributor.authorTurgutalp, Kenan
dc.contributor.authorArici, Mustafa
dc.contributor.authorOdabas, Ali Riza
dc.contributor.authorAltiparmak, Mehmet Riza
dc.contributor.authorAydin, Zeki
dc.contributor.authorCebeci, Egemen
dc.date.accessioned2024-08-04T20:49:07Z
dc.date.available2024-08-04T20:49:07Z
dc.date.issued2020
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground. Chronic kidney disease (CKD) and immunosuppression, such as in renal transplantation (RT), stand as one of the established potential risk factors for severe coronavirus disease 2019 (COVID-19). Case morbidity and mortality rates for any type of infection have always been much higher in CKD, haemodialysis (HD) and RT patients than in the general population. A large study comparing COVID-19 outcome in moderate to advanced CKD (Stages 3-5), HD and RT patients with a control group of patients is still lacking. Methods. We conducted a multicentre, retrospective, observational study, involving hospitalized adult patients with COVID-19 from 47 centres in Turkey. Patients with CKD Stages 3-5, chronic HD and RT were compared with patients who had COVID-19 but no kidney disease. Demographics, comorbidities, medications, laboratory tests, COVID-19 treatments and outcome [in-hospital mortality and combined in-hospital outcome mortality or admission to the intensive care unit (ICU)] were compared. Results. A total of 1210 patients were included [median age, 61 (quartile 1-quartile 3 48-71) years, female 551 (45.5%)] composed of four groups: control (n = 450), HD (n = 390), RT (n = 81) and CKD (n = 289). The ICU admission rate was 266/1210 (22.0%). A total of 172/1210 (14.2%) patients died. The ICU admission and in-hospital mortality rates in the CKD group [114/289 (39.4%); 95% confidence interval (CI) 33.9-45.2; and 82/289 (28.4%); 95% CI 23.9-34.5)] were significantly higher than the other groups: HD = 99/390 (25.4%; 95% CI 21.3-29.9; P < 0.001) and 63/390 (16.2%; 95% CI 13.0-20.4; P < 0.001); RT = 17/81 (21.0%; 95% CI 13.2-30.8; P = 0.002) and 9/81 (11.1%; 95% CI 5.7-19.5; P = 0.001); and control = 36/450 (8.0%; 95% CI 5.8-10.8; P < 0.001) and 18/450 (4%; 95% CI 2.5-6.2; P < 0.001). Adjusted mortality and adjusted combined outcomes in CKD group and HD groups were significantly higher than the control group [hazard ratio (HR) (95% CI) CKD: 2.88 (1.52-5.44); P = 0.001; 2.44 (1.35-4.40); P = 0.003; HD: 2.32 (1.21-4.46); P = 0.011; 2.25 (1.23-4.12); P = 0.008), respectively], but these were not significantly different in the RT from in the control group [HR (95% CI) 1.89 (0.76-4.72); P = 0.169; 1.87 (0.81-4.28); P = 0.138, respectively]. Conclusions. Hospitalized COVID-19 patients with CKDs, including Stages 3-5 CKD, HD and RT, have significantly higher mortality than patients without kidney disease. Stages 3-5 CKD patients have an in-hospital mortality rate as much as HD patients, which may be in part because of similar age and comorbidity burden. We were unable to assess if RT patients were or were not at increased risk for in-hospital mortality because of the relatively small sample size of the RT patients in this study.en_US
dc.description.sponsorshipTurkish Society of Nephrologyen_US
dc.description.sponsorshipThe study was funded by Turkish Society of Nephrology.en_US
dc.identifier.doi10.1093/ndt/gfaa271
dc.identifier.endpage2095en_US
dc.identifier.issn0931-0509
dc.identifier.issn1460-2385
dc.identifier.issue12en_US
dc.identifier.pmid33275763en_US
dc.identifier.scopus2-s2.0-85097310948en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage2083en_US
dc.identifier.urihttps://doi.org/10.1093/ndt/gfaa271
dc.identifier.urihttps://hdl.handle.net/11616/99662
dc.identifier.volume35en_US
dc.identifier.wosWOS:000607840600010en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofNephrology Dialysis Transplantationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOVID-19en_US
dc.subjecthaemodialysisen_US
dc.subjectkidney diseaseen_US
dc.subjectmortalityen_US
dc.subjectrenal transplantationen_US
dc.titleMortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu